Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

3 Stocks to Buy Before 2024 That Can Set You Up For Life: https://g.foolcdn.com/editorial/images/757806/a-couple-smiling-and-talking-with-an-advisor.jpg
3 Stocks to Buy Before 2024 That Can Set You Up For Life

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?: https://g.foolcdn.com/editorial/images/757807/a-couple-counting-money.jpg
Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?: https://g.foolcdn.com/editorial/images/757807/a-couple-counting-money.jpg
Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/758152/device-investor-getty.jpg
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/758152/device-investor-getty.jpg
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
Why Vertex Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/758217/break-through-ceiling.jpg
Why Vertex Stock Is Soaring Today

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Why Vertex Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/758217/break-through-ceiling.jpg
Why Vertex Stock Is Soaring Today

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Why Vertex Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/758217/break-through-ceiling.jpg
Why Vertex Stock Is Soaring Today

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Why Pfizer Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/758185/stock-chart-trending-down-with-man.jpg
Why Pfizer Stock Is Sinking Today

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

Why Pfizer Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/758185/stock-chart-trending-down-with-man.jpg
Why Pfizer Stock Is Sinking Today

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

1 Biotech Stock That Could Be the Next Amgen: https://g.foolcdn.com/editorial/images/758114/innovation.jpg
1 Biotech Stock That Could Be the Next Amgen

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

1 Biotech Stock That Could Be the Next Amgen: https://g.foolcdn.com/editorial/images/758114/innovation.jpg
1 Biotech Stock That Could Be the Next Amgen

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

1 Biotech Stock That Could Be the Next Amgen: https://g.foolcdn.com/editorial/images/758114/innovation.jpg
1 Biotech Stock That Could Be the Next Amgen

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

2 Big-Name Stocks Are Falling Wednesday -- Here's Why: https://g.foolcdn.com/editorial/images/758168/vaccine-gettyimages-1298099807.jpg
2 Big-Name Stocks Are Falling Wednesday -- Here's Why

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

2 Big-Name Stocks Are Falling Wednesday -- Here's Why: https://g.foolcdn.com/editorial/images/758168/vaccine-gettyimages-1298099807.jpg
2 Big-Name Stocks Are Falling Wednesday -- Here's Why

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?: https://g.foolcdn.com/editorial/images/758050/biotech.jpg
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?: https://g.foolcdn.com/editorial/images/758050/biotech.jpg
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?: https://g.foolcdn.com/editorial/images/758050/biotech.jpg
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive